Colorectal NSSG Audit Day - Polyp Cancers Northumbria Healthcare NHS Trust Sarah Mills.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

West Midlands Cancer Intelligence Unit Opportunities to Work with the WMCIU on Colorectal Cancer Projects 29 March 2010 Dr Gill Lawrence Director, West.
Geraldine O’Dowd Consultant Pathologist NHS Lanarkshire 18 th November 2014 Colorectal Cancer Pathology: Impact of new guidelines for the laboratory.
North Tees University Hospital Audit of T1 Rectal Cancers September 2013 – August 2014 Nicola Maguire Teaching fellow General Surgery 12/09/2014.
Polyps – Where do they come from and what do you do with them?!
Management of Malignant Polyps Santhat Nivatvongs, MD Colon and Rectal Surgery Mayo Clinic Rochester Minnesota U.S.A.
Role of colonoscopy in the treatment of malignant polyps Pathology of malignant colorectal polyps Assessing the risk of residual disease post-polypectomy.
DCIS – Are we cutting it? Dr Alex Lemaigre With thanks to:
The Adenoma/Carcinoma Sequence in the Colon
National Oesophago–Gastric Cancer Audit Comparing local and national figures.
Critical Book Review Due Dates March 3 rd -1 pg summary due (what you have read to this date, not the whole book)- 25pts March 10 th –Project proposal.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
Skin Lesion Excision Audit August 2013 – December 2013.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Joint Hospital Surgical Grand Round 19 June 2004.
Reporting and Management of Early stage Colorectal Cancer Frank Carey Dundee.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Treatment of Early Malignant Rectal Polyp
Audit of EGFR mutation testing in patients with proven Non-Small Cell Lung Cancer On behalf of the North of England Cancer Network Lung NSSG Dr Naomi Chamberlin,
Polyp Cancers Freeman & RVI Newcastle upon Tyne Stefan Plusa
Comparative quantitative evaluation of the XIAP, survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients.
How are we doing? Quality in Breast Cancer Care Dr Michelle Goecke Surgical Oncology Network Update October 18, 2014.
Not for reproduction IT Infrastructure NHS BCSP Julietta Patnick November 2007.
Colonoscopy; Surveillance Indications
Colorectal carcinoma Dr.Mohammadzadeh.
NORCCAG audit report 2011: mortality, survival and reconstructive rectal surgery David W Borowski for the members of the Northern Region Colorectal Cancer.
Northern Region Colorectal Cancer Audit (NORCCAG) Colorectal NSSG – Audit meeting 1 st April 2006 – 31 st July 2010 Dorothy Simms – Audit Co-ordinator.
Colorectal cancer Khayal AlKhayal MD,FRCSC Assistant professor of Surgery Consultant Colorectal surgeon 9/11/2015Shwartz.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Colon Cancer. Multihit Concept Clinical Information Clinical Information 1. Patient identification a. Name b. Identification number c. Age (birth date)
Datum/Vortragsthema Local resection of Rectum tumors Peter M. Markus Elisabeth Hospital Essen Germany.
Prognosis of colon cancer compared with rectal cancer. Where lies the difference? Bjørn S. Nedrebø Stavanger University Hospital.
LCC REC-1 Φ π π π Φ Φ See Primary and Adjuvant Treatment (LCC REC-3) Observe or See Primary Treatment (LCC REC-3) Rectal Cancer.
MALIGNANT POLYPS DURING THE FIRST THREE SCREENING ROUNDS ( ) FOR COLON-RECTAL CANCER (CRC) IN A NORTH-EASTERN SANITARY DISTRICT (ULSS-1 VENETO).
Rachel Rowlands 17 th May  2012 Be Clear on Cancer campaign  Aims of the study  Methodology  Results  Conclusions  Limitations  Recommendations.
CANCER National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
Northern Region Colorectal Liver Metastases Study Guru Raghavendra.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
Kyung Hee University, Seoul, Korea Conference LGI Conference Presented by Byeong-Joo Noh Supervised by Youn-Wha Kim Kyung Hee University, Seoul, Korea.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.
Factors affecting failed localisation and false-negative rates of ex-vivo sentinel lymph node mapping in colorectal cancer. Sommariva A, Gnocato B, Tollot.
The New trends in the Management of Breast Cancer 謝渙發 桃園縣醫師公會監事 怡仁綜合醫院副院長 教育部部定助理教授 國防醫學院外科學系臨床教授.
Per-Anders Abrahamsson Department of Urology Malmö University Hospital
Oesophago–Gastric Cancer
Principles of oncology
Dr.Amit Gupta Associate Professor Dept. of Surgery
UNDERWRITING CANCER OUR WAY OR THE LONG WAY
National Bowel Cancer Audit
Oesophago–Gastric Cancer
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 PRINCE CHARLES HOSPITAL (PCH) MDT.
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 YSBYTY GLAN CLWYD (YGC) MDT.
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 BRONGLAIS HOSPITAL (BRONGLAIS) MDT.
Oesophago–Gastric Cancer
معيارهاي ارزشيابي برنامه ثبت سرطان دانشگاهي ارسال به موقع اطلاعات (هر سه ماه)(2) گردآوري از لحاظ پيدا كردن موارد جديد سرطاني از منابع ذيل: - ثبت.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
College of American Pathologists
Polyp Cancers Freeman & RVI Newcastle upon Tyne Stefan Plusa
It’s All in the “Swerve of the Curve”
Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.
Changes in TNM 8 To be used from
LOCAL EXCISION IN DOWNSTAGED T2T3 LOW RECTAL CANCER 5-year results of the GRECCAR 2 trial E Rullier, V Vendrely, P Rouanet, JJ Tuech, A Valverde, B Lelong,
Figure 1 The spread of colorectal cancer metastases
Presentation transcript:

Colorectal NSSG Audit Day - Polyp Cancers Northumbria Healthcare NHS Trust Sarah Mills

Inclusion criteria & Outcome Measures* *Suggested 23 rd June 2014 Inclusion criteria Date of diagnosis 1 st April 2010 – 31 st March 2014 Final pathological staging = T1, M0 Outcome measures Age Sex Local excision; Yes/No Major resection; Yes/No – If yes, residual disease; Yes/No – If yes, lymph node metastases; Yes/No 90/7 mortality

Denominator/Context CRC NHCT Date Dx 1/4/10 – 31/3/14; n= (4.3%) cases excluded (referred N/Cle Rx) N=1199 M:F = 1.38:1 Mean age = 71 (29-100) M0, pT1; n=130 (10.8%)* *+ 9 ypT1 + 1 cpT ypT0

NB No 90/7 Mortality

? Local Resection ? Recurrence ? Avoid Resection

Kikuchi or Haggitt Stage; 82/96 (85%) Local resections

Reporting of risk factors* *? Case for synoptic reporting vs quality specimens Kikuchi or Haggitt stage; 85% (some fence-sitting) Resection margin; 68.8% Degree differentiation; 88.5% Mucinous; 2.1% (ie only if +ve?) Tumour budding; 1.0% (ie only if +ve?) Lymphovascular invasion; 35.4%